Prothena Corporation plc Logo

Email this page: News Release

Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders

For security reasons, registration is required before you can use this feature.
* Indicates required field